Bessemer Group Inc. Sells 15,801 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Bessemer Group Inc. lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 634,039 shares of the medical research company's stock after selling 15,801 shares during the period. Bessemer Group Inc. owned 0.17% of Thermo Fisher Scientific worth $329,847,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Stonegate Investment Group LLC raised its holdings in Thermo Fisher Scientific by 0.3% during the 4th quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company's stock worth $3,531,000 after purchasing an additional 18 shares during the last quarter. Semus Wealth Partners LLC raised its stake in Thermo Fisher Scientific by 4.0% during the fourth quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock worth $245,000 after buying an additional 18 shares during the last quarter. Bangor Savings Bank lifted its holdings in Thermo Fisher Scientific by 6.0% in the fourth quarter. Bangor Savings Bank now owns 334 shares of the medical research company's stock valued at $174,000 after buying an additional 19 shares during the period. Eagle Rock Investment Company LLC grew its holdings in Thermo Fisher Scientific by 0.3% during the 4th quarter. Eagle Rock Investment Company LLC now owns 7,463 shares of the medical research company's stock worth $3,882,000 after acquiring an additional 19 shares during the period. Finally, KRS Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 1.5% in the 4th quarter. KRS Capital Management LLC now owns 1,317 shares of the medical research company's stock valued at $685,000 after purchasing an additional 20 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Thermo Fisher Scientific Stock Performance

TMO stock traded up $6.65 during midday trading on Monday, hitting $444.80. The company's stock had a trading volume of 1,082,556 shares, compared to its average volume of 1,696,511. Thermo Fisher Scientific Inc. has a 1 year low of $409.85 and a 1 year high of $627.88. The stock has a market cap of $167.81 billion, a price-to-earnings ratio of 26.91, a PEG ratio of 2.99 and a beta of 0.86. The stock's 50-day moving average price is $510.56 and its 200 day moving average price is $538.78. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date is Friday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's dividend payout ratio is currently 10.41%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Barclays lowered their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a report on Thursday. Raymond James reissued an "outperform" rating and set a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. StockNews.com raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, January 14th. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price objective on the stock in a research report on Friday, January 10th. Finally, Citigroup decreased their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $647.43.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the transaction, the executive vice president now owns 16,363 shares in the company, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.